Go Pro

Barclays (BCS) 10K Form and Latest SEC Filings 2026

Barclays logo
$27.00 0.00 (0.00%)
As of 09/4/2026 03:58 PM Eastern

Latest Barclays SEC Filings & Recent Activity

Barclays (NYSE:BCS) has submitted 1,029+ documents to the U.S. Securities and Exchange Commission (SEC) since 2017. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Barclays's financial statements. The most recent filing was a Form N-PX submitted on September 4, 2026.

20-F
Barclays Files Annual Report on Feb. 10, 2026

The 20-F contains Barclays's audited financial statements, revenue, earnings, and risk factors for the prior fiscal year.

View earnings history

Barclays SEC Filing History

Browse Barclays' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
09/04/2026 10:00 AM
Barclays (312069) Filer
Form N-PX
Annual Report of Proxy Voting Record of Registered Management Investment Company  
09/03/2026 2:24 PM
Barclays (312069) Reporting
QVC Group, Inc. (1254699) Issuer
Form 3
Initial statement of beneficial ownership of securities  
09/01/2026 10:04 AM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/19/2026 11:31 AM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/14/2026 4:40 PM
Barclays (312069) Filed by
Rising Dragon Acquisition Corp. (2018145) Subject
Form SCHEDULE 13G/A
08/13/2026 6:38 PM
Barclays (312069) Filed by
REVIVA PHARMACEUTICALS HOLDINGS, INC. (1742927) Subject
REVIVA PHARMACEUTICALS HOLDINGS, INC. (1742927) Subject
Form SCHEDULE 13G/A
08/13/2026 6:24 PM
Barclays (312069) Filed by
Range Capital Acquisition Corp. (2035644) Subject
Range Capital Acquisition Corp. (2035644) Subject
Form SCHEDULE 13G/A
08/13/2026 6:24 PM
Barclays (312069) Filed by
Tavia Acquisition Corp. (2020385) Subject
Tavia Acquisition Corp. (2020385) Subject
Form SCHEDULE 13G/A
08/13/2026 6:11 PM
Barclays (312069) Filed by
BEL FUSE INC /NJ (729580) Subject
BEL FUSE INC /NJ (729580) Subject
Form SCHEDULE 13G/A
08/13/2026 6:11 PM
Barclays (312069) Filed by
EVERSPIN TECHNOLOGIES INC. (1438423) Subject
Form SCHEDULE 13G/A
08/13/2026 6:11 PM
Barclays (312069) Filed by
Zentalis Pharmaceuticals, Inc. (1725160) Subject
Form SCHEDULE 13G/A
08/13/2026 6:12 PM
Barclays (312069) Filed by
NewHold Investment Corp. III (2043699) Subject
Form SCHEDULE 13G/A
08/13/2026 6:12 PM
Barclays (312069) Filed by
Madison Square Garden Entertainment Corp. (1952073) Subject
Form SCHEDULE 13G/A
08/13/2026 5:47 PM
Barclays (312069) Filed by
Lakeshore Acquisition III Corp. (2049248) Subject
Lakeshore Acquisition III Corp. (2049248) Subject
Lakeshore Acquisition III Corp. (2049248) Subject
Form SCHEDULE 13G/A
08/13/2026 5:47 PM
Barclays (312069) Filed by
Launch Two Acquisition Corp. (2023676) Subject
Launch Two Acquisition Corp. (2023676) Subject
Form SCHEDULE 13G/A
08/13/2026 5:47 PM
Barclays (312069) Filed by
Roman DBDR Acquisition Corp. II (2032528) Subject
Form SCHEDULE 13G
08/13/2026 5:47 PM
Barclays (312069) Filed by
Penumbra Inc (1321732) Subject
Form SCHEDULE 13G
08/13/2026 5:47 PM
Axiom Intelligence Acquisition Corp 1 (2057030) Subject
Axiom Intelligence Acquisition Corp 1 (2057030) Subject
Axiom Intelligence Acquisition Corp 1 (2057030) Subject
Barclays (312069) Filed by
Form SCHEDULE 13G
08/13/2026 5:34 PM
Barclays (312069) Filed by
Cartesian Therapeutics, Inc. (1453687) Subject
Form SCHEDULE 13G
08/13/2026 5:34 PM
Barclays (312069) Filed by
Liberty Broadband Corp (1611983) Subject
Liberty Broadband Corp (1611983) Subject
Liberty Broadband Corp (1611983) Subject
Form SCHEDULE 13G/A
08/13/2026 5:34 PM
Barclays (312069) Filed by
CH4 Natural Solutions Corp (2044817) Subject
CH4 Natural Solutions Corp (2044817) Subject
Form SCHEDULE 13G
08/13/2026 5:34 PM
Barclays (312069) Filed by
Oaktree Acquisition Corp. III Life Sciences (2029769) Subject
Oaktree Acquisition Corp. III Life Sciences (2029769) Subject
Form SCHEDULE 13G
08/13/2026 5:21 PM
Barclays (312069) Filed by
ProCap Acquisition Corp (2056634) Subject
Form SCHEDULE 13G
08/13/2026 5:22 PM
Barclays (312069) Filed by
FORWARD AIR CORP (912728) Subject
Form SCHEDULE 13G
08/13/2026 5:22 PM
Barclays (312069) Filed by
OFFICE PROPERTIES INCOME TRUST (1456772) Subject
OFFICE PROPERTIES INCOME TRUST (1456772) Subject
Form SCHEDULE 13G
08/10/2026 10:53 AM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/07/2026 11:45 AM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/06/2026 10:51 AM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/03/2026 12:05 PM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/03/2026 6:27 AM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/30/2026 12:38 PM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/07/2026 9:08 AM
Barclays (312069) Filer
Form CERT
07/01/2026 6:54 AM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/26/2026 1:20 PM
Barclays (312069) Filer
Form 8-A12B
06/26/2026 11:57 AM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/25/2026 6:14 AM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/24/2026 11:32 AM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/22/2026 11:38 AM
Barclays (312069) Filer
Form 424B2
Transaction specifc information for a delayed shelf offering
06/22/2026 5:12 AM
Barclays (312069) Subject
Form FWP
06/22/2026 5:18 AM
Barclays (312069) Subject
Form FWP
06/22/2026 5:06 AM
Barclays (312069) Subject
Form FWP
The end may be near for these iconic stocks (Ad)

Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel

Watch Marc Chaikin's free presentation and get his full buy-and-sell list today
06/18/2026 6:58 AM
Barclays (312069) Filer
Form 424B2
Transaction specifc information for a delayed shelf offering
06/16/2026 11:23 AM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/05/2026 12:59 PM
BARCLAYS BANK PLC (312070) Filer
BARCLAYS BANK PLC (312070) Filer
BARCLAYS BANK PLC (312070) Filer
BARCLAYS BANK PLC (312070) Filer
BARCLAYS BANK PLC (312070) Filer
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/01/2026 5:01 AM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/26/2026 12:24 PM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/15/2026 10:32 AM
Barclays (312069) Filed by
XANADU QUANTUM TECHNOLOGIES FORMER SPAC INC. (2054174) Subject
XANADU QUANTUM TECHNOLOGIES FORMER SPAC INC. (2054174) Subject
Form SCHEDULE 13G/A
05/15/2026 7:40 AM
Barclays (312069) Filed by
Centurion Acquisition Corp. (2010930) Subject
Centurion Acquisition Corp. (2010930) Subject
Form SCHEDULE 13G
05/14/2026 8:52 PM
Barclays (312069) Filed by
Range Capital Acquisition Corp. (2035644) Subject
Range Capital Acquisition Corp. (2035644) Subject
Form SCHEDULE 13G/A
05/14/2026 8:46 PM
Barclays (312069) Filed by
Talkspace, Inc. (1803901) Subject
Talkspace, Inc. (1803901) Subject
Talkspace, Inc. (1803901) Subject
Form SCHEDULE 13G
05/14/2026 8:22 PM
Barclays (312069) Filed by
Calisa Acquisition Corp (2026767) Subject
Calisa Acquisition Corp (2026767) Subject
Calisa Acquisition Corp (2026767) Subject
Form SCHEDULE 13G
05/14/2026 8:23 PM
Barclays (312069) Filed by
SilverBox Corp IV (2015947) Subject
Form SCHEDULE 13G
05/14/2026 8:23 PM
Barclays (312069) Filed by
Graf Global Corp. (1897463) Subject
Form SCHEDULE 13G
05/14/2026 8:24 PM
Andretti Acquisition Corp. II (2025341) Subject
Andretti Acquisition Corp. II (2025341) Subject
Barclays (312069) Filed by
Form SCHEDULE 13G/A
05/14/2026 8:25 PM
Barclays (312069) Filed by
Gores Holdings X, Inc. / CI (1986817) Subject
Gores Holdings X, Inc. / CI (1986817) Subject
Form SCHEDULE 13G
05/14/2026 8:25 PM
Barclays (312069) Filed by
BEL FUSE INC /NJ (729580) Subject
BEL FUSE INC /NJ (729580) Subject
Form SCHEDULE 13G
05/14/2026 8:25 PM
Barclays (312069) Filed by
REVIVA PHARMACEUTICALS HOLDINGS, INC. (1742927) Subject
REVIVA PHARMACEUTICALS HOLDINGS, INC. (1742927) Subject
Form SCHEDULE 13G
05/14/2026 8:26 PM
Barclays (312069) Filed by
MERCER INTERNATIONAL INC. (1333274) Subject
Form SCHEDULE 13G
05/14/2026 8:27 PM
Barclays (312069) Filed by
Star Holdings (1953366) Subject
Form SCHEDULE 13G/A
05/14/2026 8:27 PM
AMICUS THERAPEUTICS, INC. (1178879) Subject
Barclays (312069) Filed by
Form SCHEDULE 13G
05/14/2026 8:28 PM
Barclays (312069) Filed by
MASIMO CORP (937556) Subject
Form SCHEDULE 13G
05/14/2026 8:29 PM
Barclays (312069) Filed by
Tavia Acquisition Corp. (2020385) Subject
Tavia Acquisition Corp. (2020385) Subject
Form SCHEDULE 13G
05/14/2026 8:31 PM
Barclays (312069) Filed by
JELD-WEN Holding, Inc. (1674335) Subject
Form SCHEDULE 13G
05/14/2026 7:38 PM
Barclays (312069) Filed by
Lakeshore Acquisition III Corp. (2049248) Subject
Lakeshore Acquisition III Corp. (2049248) Subject
Lakeshore Acquisition III Corp. (2049248) Subject
Form SCHEDULE 13G
05/14/2026 7:40 PM
Barclays (312069) Filed by
Odysseus (0) Cayman
Form SCHEDULE 13G/A
05/14/2026 7:40 PM
Barclays (312069) Filed by
RADCOM LTD (1016838) Subject
Form SCHEDULE 13G/A
05/14/2026 7:41 PM
Barclays (312069) Filed by
Soulpower Acquisition Corp. (2025608) Subject
Form SCHEDULE 13G/A
05/14/2026 7:42 PM
Barclays (312069) Filed by
SHENANDOAH TELECOMMUNICATIONS CO/VA/ (354963) Subject
Form SCHEDULE 13G/A
05/14/2026 7:43 PM
Barclays (312069) Filed by
Melar Acquisition Corp. I/Cayman (2016221) Subject
Melar Acquisition Corp. I/Cayman (2016221) Subject
Form SCHEDULE 13G/A
05/14/2026 7:44 PM
Barclays (312069) Filed by
Cantor Equity Partners II, Inc. (2034269) Subject
Form SCHEDULE 13G/A
05/14/2026 7:47 PM
Barclays (312069) Filed by
James River Group Holdings, Inc. (1620459) Subject
Form SCHEDULE 13G/A
05/14/2026 7:48 PM
Barclays (312069) Filed by
PHIBRO ANIMAL HEALTH CORP (1069899) Subject
Form SCHEDULE 13G/A
05/14/2026 7:49 PM
Barclays (312069) Filed by
WEN Acquisition Corp (2057043) Subject
Form SCHEDULE 13G/A
05/14/2026 7:50 PM
Barclays (312069) Filed by
Centurion Acquisition Corp. (2010930) Subject
Centurion Acquisition Corp. (2010930) Subject
Form SCHEDULE 13G/A
05/14/2026 7:34 PM
Barclays (312069) Filed by
CO2 Energy Transition Corp. (1956648) Subject
CO2 Energy Transition Corp. (1956648) Subject
CO2 Energy Transition Corp. (1956648) Subject
Form SCHEDULE 13G
05/14/2026 7:34 PM
Barclays (312069) Filed by
Madison Square Garden Entertainment Corp. (1952073) Subject
Form SCHEDULE 13G
05/12/2026 1:44 PM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/12/2026 1:06 PM
Barclays (312069) Filed by
EVERSPIN TECHNOLOGIES INC. (1438423) Subject
Form SCHEDULE 13G/A
05/12/2026 10:34 AM
Barclays (312069) Subject
NEW YORK STOCK EXCHANGE LLC (876661) Filed by
Form 25-NSE
05/11/2026 10:30 AM
Barclays (312069) Subject
NEW YORK STOCK EXCHANGE LLC (876661) Filed by
Form 25-NSE
05/07/2026 1:58 PM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/07/2026 12:13 PM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/29/2026 12:54 PM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/29/2026 5:19 AM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/28/2026 6:00 AM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/13/2026 12:37 PM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/07/2026 3:02 PM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/01/2026 6:41 AM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/31/2026 2:11 PM
Barclays (312069) Filer
Form 13F-HR/A
03/31/2026 10:10 AM
Barclays (312069) Filer
Form 13F-HR/A
03/30/2026 7:05 AM
Barclays (312069) Filer
Form 13F-HR/A
My top 3 AI picks for the next decade (Ad)

Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.tc pixel

Click here to get all three AI stock names from Alexander Green
03/30/2026 7:11 AM
Barclays (312069) Filer
Form 13F-HR/A
03/30/2026 7:11 AM
Barclays (312069) Filer
Form 13F-HR/A
03/27/2026 7:17 AM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/25/2026 5:52 AM
Barclays (312069) Filer
Form 13F-HR/A
03/24/2026 1:30 PM
Barclays (312069) Filer
Form 13F-HR/A
03/23/2026 12:21 PM
Barclays (312069) Filer
Form 13F-HR/A
03/19/2026 4:15 PM
Barclays (312069) Filer
Form 13F-HR/A
03/19/2026 3:01 PM
Barclays (312069) Filer
Form 13F-HR/A
03/18/2026 1:18 PM
Barclays (312069) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
(Data available from 1/1/2016 forward)

Barclays SEC Filings - Frequently Asked Questions

Barclays (BCS) has submitted 1,029+ filings to the SEC since 2017. You can browse the complete history or filter by form type using the tools above.

Barclays's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Barclays's financial statements page.

The most recent filing was a Form N-PX submitted on September 4, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


SEC filings for NYSE:BCS are sourced directly from the U.S. Securities and Exchange Commission (SEC), with the most recent filing dated 9/4/2026. New filings are added as they're published.
From Our Partners